Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/51163
Campo DC Valoridioma
dc.contributor.authorÁlvarez-Prats, Alejandroen_US
dc.contributor.authorHernández-Perera, Octavioen_US
dc.contributor.authorDíaz-Herrera, Pilaren_US
dc.contributor.authorUcero, Álvaro C.en_US
dc.contributor.authorAnabitarte-Prieto, Aránzazuen_US
dc.contributor.authorLosada-Cabrera, Antonioen_US
dc.contributor.authorOrtiz, Albertoen_US
dc.contributor.authorRodriguez-Perez, Jose C.en_US
dc.contributor.otherRodriguez-Perez, J.C.-
dc.contributor.otherUcero, Alvaro-
dc.contributor.otherortiz, alberto-
dc.date.accessioned2018-11-24T22:01:26Z-
dc.date.available2018-11-24T22:01:26Z-
dc.date.issued2012en_US
dc.identifier.issn0931-0509en_US
dc.identifier.urihttp://hdl.handle.net/10553/51163-
dc.description.abstractBackground Angiotensin receptor 1 blockers (ARB) are standard nephroprotective drugs in chronic kidney disease. There is less evidence for a nephroprotective effect of HMG-CoA reductase inhibitors (statins) and much less is known about potential benefits of combination therapy. We evaluated the therapeutic potential of a statin alone or in combination with an ARB in experimental chronic kidney disease. Methods Subtotally nephrectomized (5/6 Nx) rats were treated early with vehicle, losartan, cerivastatin or losartan/cerivastatin. Expression of messenger RNA (mRNA) was assessed by real-time reverse transcriptionpolymerase chain reaction. Tissue proteins were localized by immunohistochemistry. Nuclear factor-κB (NF-κB) activation was measured in whole kidneys. Results In contrast to the sham group, at 6 weeks, vehicle-treated 5/6 Nx rats displayed renal lesions, albuminuria and increased blood pressure, serum creatinine and total kidney NF-κB p65 DNA-binding activity and preproendothelin-1, fibronectin and type I and III collagen mRNA. NF-κB activation correlated with albuminuria and histological renal injury. Losartan or combination therapy preserved renal function, abrogated albuminuria and improved glomerular and interstitial histology. Cerivastatin alone preserved renal function and improved interstitial injury but did not influence albuminuria, glomerular histology or NF-κB activation. Losartan/cerivastatin normalized kidney NF-κB activation and extracellular matrix mRNA expression pattern. The effect of losartan alone on these parameters was less intense. All treatments decreased preproendothelin-1 mRNA and preserved interstitial capillaries. Conclusions In a chronic kidney disease model, early treatment with either an ARB or a statin preserved renal function although the mechanisms differed. Combination therapy with an ARB and a statin did not confer clear-cut advantages on biochemical and histological parameters over ARB alone, although it further improved the kidney NF-κB and gene expression profile.en_US
dc.languageengen_US
dc.relation.ispartofNephrology Dialysis Transplantationen_US
dc.sourceNephrology Dialysis Transplantation[ISSN 0931-0509],v. 27 (7), p. 2720-2733 (Julio 2012)en_US
dc.subject32 Ciencias médicasen_US
dc.subject320506 Nefrologíaen_US
dc.subject.otherAngiotensin II receptor blockeren_US
dc.subject.otherHMG-CoA reductase inhibitoren_US
dc.subject.otherNF-κBen_US
dc.subject.otherSubtotal nephrectomyen_US
dc.titleCombination therapy with an angiotensin II receptor blocker and an HMG-CoA reductase inhibitor in experimental subtotal nephrectomyen_US
dc.typeinfo:eu-repo/semantics/Articleen_US
dc.typeArticleen_US
dc.identifier.doi10.1093/ndt/gfr671en_US
dc.identifier.scopus84864415082-
dc.identifier.isi000306669100019-
dcterms.isPartOfNephrology Dialysis Transplantation-
dcterms.sourceNephrology Dialysis Transplantation[ISSN 0931-0509],v. 27 (7), p. 2720-2733-
dc.contributor.authorscopusid55324275100-
dc.contributor.authorscopusid6602270309-
dc.contributor.authorscopusid7801586700-
dc.contributor.authorscopusid23476205700-
dc.contributor.authorscopusid6506385286-
dc.contributor.authorscopusid6506654671-
dc.contributor.authorscopusid7201911399-
dc.contributor.authorscopusid7005446255-
dc.description.lastpage2733en_US
dc.description.firstpage2720en_US
dc.relation.volume27en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.identifier.wosWOS:000306669100019-
dc.contributor.daisngid4950631-
dc.contributor.daisngid3571462-
dc.contributor.daisngid6834878-
dc.contributor.daisngid1670953-
dc.contributor.daisngid10185782-
dc.contributor.daisngid11789635-
dc.contributor.daisngid26154-
dc.contributor.daisngid245684-
dc.identifier.investigatorRIDC-1247-2010-
dc.identifier.investigatorRIDC-8437-2013-
dc.identifier.investigatorRIDY-7582-2018-
dc.description.numberofpages14en_US
dc.utils.revisionen_US
dc.date.coverdateJulio 2012en_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr1,673-
dc.description.jcr3,371-
dc.description.sjrqQ1-
dc.description.jcrqQ1-
dc.description.scieSCIE-
item.grantfulltextnone-
item.fulltextSin texto completo-
crisitem.author.deptDepartamento de Morfología-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.orcid0000-0003-0023-1063-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameDíaz Herrera, María Del Pilar-
crisitem.author.fullNameRodríguez Pérez,José Carlos-
Colección:Artículos
Vista resumida

Citas SCOPUSTM   

10
actualizado el 30-mar-2025

Citas de WEB OF SCIENCETM
Citations

9
actualizado el 30-mar-2025

Visitas

143
actualizado el 22-feb-2025

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.